Alumis opened lower at $6.50, compared with its previous close of $6.62. In the last trading session, the stock traded between $6.14 and $6.61. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 3 years ago in Alumis is now worth
$ 46.20
Resulting in a loss of
$ 53.80 (53.80%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 8 Analysts
Buy
87.5%
Hold
12.5%
Sell
0%
Markets Today
Today's Change
$-0.48 (-7.18%)
Day High
$6.61
Day Low
$6.14
Day Open
$6.50
Prev Close
$6.62
Volume
13,29,919
1W Return
-6.23%
1M Return
-12.80%
3M Return
-75.79%
6M Return
-74.03%
1Y Return
15.94%
Fundamentals
Market Cap ($ Mn)
795
PE Ratio
-
PB Ratio
6.35
PEG Ratio
-
ROE
-76.05%
ROCE
-74.84%
EPS (TTM)
-
Investment Returns
1 Week
-6.23%
1 Month
-12.80%
3 Months
-75.79%
6 Months
-74.03%
9 Months
-76.02%
Financials
Quarterly
All values in $ Mn
17.4
Mar 25
2.7
Jun 25
2.1
Sep 25
1.9
Dec 25
1.7
Mar 26
1.7
Jun 26
Updates
9Oct
Alumis Phase 3 data shows 54% skin clearance in psoriasis trial
Achieved 54% PASI 100 complete skin clearance at Week 48 in ONWARD3 study. Over 80% of patients maintained clear scalp skin at 48 weeks. Nearly 80% sustained clinically meaningful itch reduction through Week 48. Plans to submit NDA for moderate-to-severe plaque psoriasis in Q4 2026.
1mo ago
4Sep
Alumis to participate in four September healthcare investor conferences
Alumis to hold fireside chats at Wells Fargo and Cantor conferences on September 8 and 9. Company will present at Morgan Stanley and Baird conferences on September 14 and 15. Live webcasts accessible via company website with 90-day archive availability. Pipeline includes envudeucitinib for psoriasis and A-005 for Parkinson’s disease.
2mo ago
1Sep
Alumis stock falls 55% as SLE trial misses primary endpoints
Alumis stock fell 54.84% to $9.850 after Phase 2b SLE trial missed endpoints. Overall population failed to meet primary BICLA endpoint at Week 48. Robust efficacy seen in prespecified high interferon gene signature subgroup. Data supports regulatory engagement for Phase 3 development with enriched enrollment. NDA for plaque psoriasis remains on track for fourth quarter 2026 submission.
2mo ago
14Aug
Alumis Q2 Results: EPS Misses Estimate, Sales Fall 37% YoY
Alumis Q2 earnings reveal a complex performance picture. While the company narrowed its per-share loss by 12.6% YoY to $(1.11), it missed analyst estimates by 56%. Revenue fell 37.66% YoY to $1.662M, missing forecasts by over 50%, indicating significant headwinds in sales generation despite improved loss margins.
3mo ago
11Aug
Alumis envudeucitinib achieves 54% PASI 100 in psoriasis study
Alumis Inc. announced topline results from the ONWARD3 long-term extension study showing 54% of patients achieved PASI 100 skin clearance with envudeucitinib after 48 weeks. The company plans to submit an NDA to the FDA in Q4 2026.
